Literature DB >> 21819999

Neurobehavioral and metabolic long-term consequences of neonatal maternal deprivation stress and adolescent olanzapine treatment in male and female rats.

Alvaro Llorente-Berzal1, Virginia Mela, Erika Borcel, Manuel Valero, Meritxell López-Gallardo, Maria-Paz Viveros, Eva M Marco.   

Abstract

Early maternal deprivation (MD), 24h of dam-litter separation on postnatal day (PND) 9, has been proposed as a suitable animal model to investigate some neuropsychiatric disorders with a base in neurodevelopment that also compromises metabolic and endocrine homeostasis. Atypical antipsychotics are frequently prescribed to children and adolescents as first-line treatment for several mental disorders despite the adverse metabolic effects frequently reported. However, persistent long-term effects after adolescent drug therapy have been scarcely investigated. In the present study we aimed to investigate the long-lasting metabolic and behavioral effects of MD in combination with the administration of an atypical antipsychotic, i.e. olanzapine, during adolescence. For that purpose, male and female Wistar rats not exposed (control group, Co) and exposed to the MD protocol were administered with oral olanzapine (Olan, 7.5mg/kg/day) or vehicle (Vh, 1mM acetic acid) in drinking water from PND 28 to PND 49. Body weight gain, glycaemia and plasma triglyceride (TG) levels were evaluated as relevant metabolic parameters. MD significantly diminished body weight gain, while Olan administration only induced a subtle decrease in body weight gain among female animals in the long-term. Olan discontinuation decreased plasma TG levels in adult rats, an effect that was counteracted by neonatal exposure to the MD protocol. Both MD and Olan treatment impaired cognitive function in the novel object recognition test, although no interaction between treatments was observed. Neither MD nor Olan administration affected psychotic-related symptoms evaluated in the prepulse inhibition task, although animals treated with Olan showed an increased reactivity to the first acoustic stimulus. MD diminished the corticosterone stress-induced response among females, and reduced the expression of CB1 receptors in the hippocampus of both male and female rats. Notably, Olan administration tended to counterbalance these two MD-induced effects (i.e. corticosterone response and CB1 receptor expression). Present findings provide evidence for the long-lasting effects of neonatal MD and Olan administration during adolescence, and suggest some sex-dependent interactions between these two protocols. Further research on the interactions between early life stress and antipsychotic drugs is urgently needed, and sex differences should be consistently considered both in animal models and in translation to human studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21819999     DOI: 10.1016/j.neuropharm.2011.07.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.

Authors:  Elodie M Girault; Bruno Guigas; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Susanne E la Fleur; Eric Fliers; Andries Kalsbeek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

2.  Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT1A Expression and Emotional Behaviour of Male and Female Adolescent Rats.

Authors:  Lorena Henn; Natália C Zanta; Carlos Eduardo N Girardi; Deborah Suchecki
Journal:  Mol Neurobiol       Date:  2020-10-15       Impact factor: 5.590

3.  Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet.

Authors:  Virginia Mela; Fabiana Piscitelli; Alvaro Llorente Berzal; Julie Chowen; Cristoforo Silvestri; Maria Paz Viveros; Vincenzo Di Marzo
Journal:  J Physiol Biochem       Date:  2017-03-23       Impact factor: 4.158

4.  Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.

Authors:  Qing Shu; Gang Hu; Ming Li
Journal:  J Psychopharmacol       Date:  2013-11-20       Impact factor: 4.153

5.  Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens.

Authors:  Su Xu; Rao P Gullapalli; Douglas O Frost
Journal:  Schizophr Res       Date:  2014-12-05       Impact factor: 4.939

6.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

7.  Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood.

Authors:  Jun Gao; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-03       Impact factor: 5.067

8.  Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.

Authors:  Jing Qiao; Qinglin Zhang; Ming Li
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-16       Impact factor: 5.067

9.  Adult rats treated with risperidone during development are hyperactive.

Authors:  Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith
Journal:  Exp Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.157

10.  Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model.

Authors:  Jing Qiao; Hong Li; Ming Li
Journal:  Neuropsychopharmacology       Date:  2012-11-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.